Literature DB >> 27660341

3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.

Fernando Gomollón1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Axel Dignass1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Vito Annese1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Herbert Tilg1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Gert Van Assche1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, James O Lindsay1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Laurent Peyrin-Biroulet1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Garret J Cullen1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Marco Daperno1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Torsten Kucharzik1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Florian Rieder1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Sven Almer1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Alessandro Armuzzi1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Marcus Harbord1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Jost Langhorst1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Miquel Sans1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Yehuda Chowers1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Gionata Fiorino1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Pascal Juillerat1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Gerassimos J Mantzaris1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Fernando Rizzello1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Stephan Vavricka1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22, Paolo Gionchetti1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16,17,18,19,20,21,22.   

Abstract

This paper is the first in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn's disease. Surgical management as well as special situations including management of perianal Crohn's disease of this ECCO Consensus are covered in a subsequent second paper [Gionchetti et al JCC 2016].
Copyright © 2016 European Crohn’s and Colitis Organisation (ECCO). Published by Oxford University Press. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Crohn’s disease; Immunosuppressant; biologics; fistulizing disease; perianal disease; steroids; strictureplasty; thiopurine; treatment; vedolizumab

Mesh：

Year:  2016        PMID： 27660341     DOI： 10.1093/ecco-jcc/jjw168

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN： 1873-9946            Impact factor:   9.071


  458 in total

1.  Effectiveness of Infliximab on Deep Radiological Remission in Chinese Patients with Perianal Fistulizing Crohn's Disease.

Authors:  Mingming Zhu; Xitao Xu; Qi Feng; Zhe Cui; Tianrong Wang; Yunqi Yan; Zhihua Ran
Journal:  Dig Dis Sci       Date:  2020-06-10       Impact factor: 3.199

2.  Crohn's disease: management in adults, children and young people - concise guidance .

Authors:  Gloria Sz Tun; Sarah Cripps; Alan J Lobo
Journal:  Clin Med (Lond)       Date:  2018-06       Impact factor: 2.659

3.  Physicians' Perspectives on Cost, Safety, and Perceived Efficacy Determine Aminosalicylate Use in Crohn's Disease.

Authors:  Christopher Ma; Carla Ascoytia; Kelly P McCarrier; Mona Martin; Brian G Feagan; Vipul Jairath
Journal:  Dig Dis Sci       Date:  2018-06-29       Impact factor: 3.199

4.  Prognostic tools for identification of high risk in people with Crohn's disease: systematic review and cost-effectiveness study.

Authors:  Steven J Edwards; Samantha Barton; Mariana Bacelar; Charlotta Karner; Peter Cain; Victoria Wakefield; Gemma Marceniuk
Journal:  Health Technol Assess       Date:  2021-03       Impact factor: 4.014

5.  Compare risk factors associated with postoperative infectious complication in Crohn's disease with and without preoperative infliximab therapy: a cohort study.

Authors:  Shasha Tang; Xue Dong; Wei Liu; Weilin Qi; Lingna Ye; Xiaoyan Yang; Qian Cao; Xiaolong Ge; Wei Zhou
Journal:  Int J Colorectal Dis       Date:  2020-02-14       Impact factor: 2.571

6.  Immunohistochemical Assessment of CD30+ Lymphocytes in the Intestinal Mucosa Facilitates Diagnosis of Pediatric Ulcerative Colitis.

Authors:  Ondrej Fabian; Ondrej Hradsky; Tereza Drskova; Filip Mikus; Josef Zamecnik; Jiri Bronsky
Journal:  Dig Dis Sci       Date:  2018-03-14       Impact factor: 3.199

7.  Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease.

Authors:  Heather Catt; Keith Bodger; Jamie J Kirkham; Dyfrig A Hughes
Journal:  Pharmacoeconomics       Date:  2019-12       Impact factor: 4.981

Review 8.  Crohn's disease.

Authors:  Giulia Roda; Siew Chien Ng; Paulo Gustavo Kotze; Marjorie Argollo; Remo Panaccione; Antonino Spinelli; Arthur Kaser; Laurent Peyrin-Biroulet; Silvio Danese
Journal:  Nat Rev Dis Primers       Date:  2020-04-02       Impact factor: 52.329

Review 9.  The current state of the art for biological therapies and new small molecules in inflammatory bowel disease.

Authors:  Sudarshan Paramsothy; Adam K Rosenstein; Saurabh Mehandru; Jean-Frederic Colombel
Journal:  Mucosal Immunol       Date:  2018-06-15       Impact factor: 7.313

10.  Comparison of Lewis Score and Capsule Endoscopy Crohn's Disease Activity Index in Patients with Crohn's Disease.

Authors:  Teppei Omori; Harutaka Kambayashi; Shun Murasugi; Ayumi Ito; Maria Yonezawa; Shinichi Nakamura; Katsutoshi Tokushige
Journal:  Dig Dis Sci       Date:  2019-09-20       Impact factor: 3.199
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.